EMPULSE: Empagliflozin Yields QOL Benefits in Patients Hospitalized for Acute HF - AJMC.com Managed Markets Network

Patients hospitalized for acute heart failure and prescribed empagliflozin saw improvements in quality of life at 15 and 90 days post-discharge. The study may make the case for prescribing SGLT2 inhibitors before patients leave the hospital.

Late breaking secondary analysis data from the EMPULSE trial revealed the initiation of empagliflozin in patients hospitalized for acute heart failure (AHF) improved symptoms, physical limitations (P… [+3162 chars]

full article...